The Rome V Criteria marks the biggest overhaul in gut-brain disorder diagnosis in a decade, with changes that could broaden access to IBS care worldwide.
For nearly three decades, the Rome Criteria have served as the international standard for diagnosing gastrointestinal disorders that lack obvious structural abnormalities on testing. The newest edition, Rome V, released in 2026, represents the most significant update since Rome IV was introduced in 2016.
The changes affect how clinicians diagnose irritable bowel syndrome (IBS), functional dyspepsia, chronic constipation, nausea and vomiting disorders, pediatric gastrointestinal disorders, and many other conditions now collectively known as Disorders of Gut-Brain Interaction (DGBIs).
While Rome V may seem like an academic update, the revisions have real-world implications for patients. Many people who previously failed to meet Rome IV criteria may now receive a diagnosis sooner, and the new framework places greater emphasis on multidisciplinary care that includes dietitians, psychologists, behavioral therapies, and medical treatment.
- The Continued Move Away From "Functional" Disorders
- Rome V Separates Clinical and Research Criteria
- The Biggest IBS Change: Discomfort Is Back
- New Diagnoses Added to the Rome Framework
- Multidisciplinary Care Moves to the Forefront
- Greater Attention to the Patient Experience
- Rome V Officially Recognizes Diet as Central to IBS Management
- Pediatric Criteria Receive a Major Overhaul
- What Rome V Means for Patients With IBS
- The Bottom Line
The Continued Move Away From “Functional” Disorders
One of the most noticeable philosophical shifts in Rome V is the continued move away from the term “functional gastrointestinal disorders.”
The Rome Foundation formally adopted the term Disorders of Gut-Brain Interaction (DGBIs) in recent years, and Rome V further minimizes use of the word “functional.” The goal is to use language that better reflects current scientific understanding while reducing stigma associated with these conditions.
Researchers now recognize that IBS and related disorders involve complex interactions among the gut microbiome, nervous system, immune system, gastrointestinal motility, and brain-gut communication. The symptoms are real, measurable, and biologically based, even when routine testing appears normal.
Rome V Separates Clinical and Research Criteria
One of the most important structural changes is the formal separation of research criteria from clinical criteria.
Under Rome IV, the same symptom thresholds were generally used both in research studies and in clinical practice. Rome V acknowledges that these are different goals.
Research criteria are designed to create highly standardized patient populations for clinical trials. Clinical criteria are intended to help healthcare providers diagnose and manage patients in everyday practice, where symptoms often do not fit neatly into rigid categories. Rome V therefore allows greater clinical judgment while maintaining scientific rigor.
For patients, this means clinicians may have more flexibility in making a diagnosis when symptoms clearly affect quality of life but do not perfectly match research definitions.
The Biggest IBS Change: Discomfort Is Back
The IBS criteria generated considerable debate during the Rome IV era.
Rome III required recurrent abdominal pain or discomfort. Rome IV eliminated discomfort and required abdominal pain at least one day per week. Many clinicians felt this excluded patients who clearly had IBS but experienced bloating, pressure, cramping, fullness, or discomfort rather than what they would specifically describe as pain.
Rome V reverses that decision.
The new criteria once again include both abdominal pain and abdominal discomfort. In addition, the symptom threshold has been lowered from weekly symptoms to at least three days per month. These changes are expected to increase the number of patients who meet diagnostic criteria and better reflect how IBS presents in clinical practice.
For many patients who previously heard, “You don’t quite meet the criteria for IBS,” this change may be particularly meaningful.
New Diagnoses Added to the Rome Framework
Rome V introduces several new diagnostic entities that have accumulated sufficient evidence over the past decade to warrant formal recognition.
These include:
- Inability to Belch Syndrome (Retrograde Cricopharyngeal Dysfunction)
- Adult Abdominal Migraine
- Anorectal Sensory Dysfunction
The addition of these diagnoses reflects growing recognition that patients with these symptoms often struggled for years without a clear diagnostic framework. Rome V incorporates them into mainstream gastroenterology for the first time.
Multidisciplinary Care Moves to the Forefront
Perhaps the most welcome change for many clinicians is Rome V’s formal embrace of multidisciplinary treatment.
Rather than focusing primarily on medications, Rome V incorporates dietary interventions, behavioral therapies, and psychological approaches alongside pharmacologic management. The framework specifically recognizes interventions such as:
Save this article
Enter your email address and we'll send it straight to your inbox.
- The low FODMAP diet
- Gut-directed cognitive behavioral therapy
- Hypnotherapy
- Biofeedback
- New pharmacologic therapies
This integrated model acknowledges what many clinicians already know: successful management of IBS and other DGBIs often requires more than a prescription alone. Dietitians, gastroenterologists, psychologists, pelvic floor specialists, and primary care providers all have important roles to play.
For those of us working in digestive health, this formal recognition is long overdue.
Greater Attention to the Patient Experience
Rome V also expands its focus on factors that influence health beyond symptoms alone.
The updated framework incorporates social determinants of health, life-stage considerations, early life experiences, and LGBTQ+ health considerations. The goal is to understand not just the symptoms a patient experiences but also the context in which those symptoms occur.
This broader perspective reflects a growing understanding that digestive disorders do not occur in isolation from a person’s environment, relationships, and life experiences.
Rome V Officially Recognizes Diet as Central to IBS Management
One of the most meaningful shifts in Rome V is the formal recognition that dietary therapy is no longer considered “alternative” or secondary care for IBS and other Disorders of Gut-Brain Interaction (DGBIs). Instead, diet is now acknowledged as a core part of evidence-based management.
For years, many IBS patients were told their symptoms were caused primarily by stress, anxiety, or vague food sensitivities. Patients often cycled through restrictive diets without guidance or were dismissed entirely when standard testing came back “normal.”
Rome V reflects how dramatically the science has evolved.
The updated framework specifically recognizes dietary interventions, including the low FODMAP diet, as part of multidisciplinary care alongside medication, behavioral therapies, gut-directed hypnotherapy, and psychological support. This validates what many gastroenterologists and dietitians have seen in clinical practice for years: food can significantly affect symptoms for many people with IBS.
Importantly, Rome V also reinforces the need for individualized care. The Elimination Phase of the low FODMAP diet is not intended to be a lifelong diet, nor is it appropriate to navigate alone whenever possible. The best outcomes occur when patients work with a dietitian trained in digestive health and DGBIs.
The broader message is encouraging. IBS is increasingly being treated as a complex condition involving the gut microbiome, nervous system, immune function, motility, and the gut-brain axis—not simply “stress” or “sensitive stomachs.”
For patients who have struggled to feel heard, Rome V represents a significant step forward.
Pediatric Criteria Receive a Major Overhaul
Rome V makes substantial changes to pediatric DGBI classification.
Rather than organizing pediatric disorders primarily by age, the new system classifies conditions according to upper and lower gastrointestinal anatomy. The criteria also expand recognition of upper GI disorders affecting children and adolescents, including feeding disorders, chronic nausea syndromes, rumination syndrome, and disorders involving belching and air transit.
Advances in diagnostic technologies such as impedance testing and high-resolution manometry are also reflected in the new pediatric framework.
What Rome V Means for Patients With IBS
For most patients, Rome V does not dramatically change treatment recommendations overnight. However, it does represent a more inclusive and realistic understanding of how IBS and other DGBIs present in the real world.
The reintroduction of discomfort into IBS criteria may allow more patients to receive a diagnosis. The separation of clinical and research criteria gives healthcare providers greater flexibility. The emphasis on multidisciplinary care validates approaches that combine dietary, behavioral, and medical interventions.
Most importantly, Rome V continues moving the field away from outdated ideas that these disorders are simply “functional” or somehow less real than conditions visible on a scan or blood test.
The Bottom Line
Rome V represents the next step in the evolution of Disorders of Gut-Brain Interaction. The new criteria reflect advances in neurogastroenterology, microbiome science, behavioral medicine, and patient-centered care. By reintroducing abdominal discomfort into IBS criteria, recognizing new disorders, embracing multidisciplinary treatment, and reducing reliance on stigmatizing terminology, Rome V brings the field closer to how patients actually experience these conditions.
For clinicians, researchers, dietitians, and patients alike, the message is clear: digestive disorders are increasingly understood as complex, biologically grounded conditions that deserve comprehensive, evidence-based care.
Resources
Rome Foundation: Rome V Diagnostic Criteria Overview
The official source for information on the new Rome V criteria and other Disorders of Gut-Brain Interaction (DGBI) guidelines.
Rome Foundation Journal Publications
Peer-reviewed papers, updates, and consensus documents related to Rome V and IBS diagnosis.
American Gastroenterological Association (AGA) IBS Resources
Patient-friendly and clinician-supported information about IBS symptoms, diagnosis, and management.
International Foundation for Gastrointestinal Disorders (IFFGD) IBS Information
Trusted nonprofit resource covering IBS symptoms, treatment approaches, and current research.
FODMAP Everyday® IBS Articles and Low FODMAP Resources
Evidence-based articles, recipes, and practical guidance for people managing IBS and other DGBIs.
Monash University Low FODMAP Diet Resources
Research-backed information from the creators of the low FODMAP diet, including diet guidance and IBS education.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) IBS Overview
Government-backed information on IBS symptoms, diagnosis, treatment, and ongoing research.
